Tobramycin in Bronchiectasis Colonized With Pseudmonas Aeruginosa
Status:
Unknown status
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
This is a phase 3 study. Patients will be enrolled from 14 medical centers in mainland China.
Eligible patients will be randomly allocated to treatment group (tobramycin nebulization,
300mg bid) and control group (natural saline nebulization, 5ml bid). A total of two 28-day
on-and-off cycles will be scheduled. Both tobramycin solution and natural saline and the
nebulizer will be solely provided by the sponsor.